PTC Therapeutics, Inc.
PTCT
$75.25
-$0.92-1.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 97.54% | 96.00% | 91.12% | -13.97% | 12.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 97.54% | 96.00% | 91.12% | -13.97% | 12.84% |
| Cost of Revenue | -16.31% | -7.16% | -10.83% | -19.15% | -23.03% |
| Gross Profit | 326.20% | 304.88% | 334.42% | 4.44% | 1,659.64% |
| SG&A Expenses | 14.51% | 8.14% | -3.23% | -9.51% | -16.18% |
| Depreciation & Amortization | -86.11% | -92.53% | -94.46% | -72.72% | -25.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.68% | -17.82% | -25.08% | -25.92% | -21.58% |
| Operating Income | 821.89% | 550.40% | 410.40% | 58.00% | 75.10% |
| Income Before Tax | 274.16% | 234.82% | 200.87% | 47.84% | 41.62% |
| Income Tax Expenses | -138.66% | 353.65% | 184.93% | 100.25% | 131.85% |
| Earnings from Continuing Operations | 265.87% | 231.21% | 202.70% | 42.02% | 29.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 265.87% | 231.21% | 202.70% | 42.02% | 29.38% |
| EBIT | 821.89% | 550.40% | 410.40% | 58.00% | 75.10% |
| EBITDA | 4,270.83% | 6,935.62% | 3,029.36% | 36.99% | 106.86% |
| EPS Basic | 261.83% | 227.01% | 198.37% | 43.52% | 31.42% |
| Normalized Basic EPS | 401.11% | 326.00% | 284.45% | 54.66% | 53.79% |
| EPS Diluted | 243.81% | 210.22% | 184.59% | 43.44% | 31.39% |
| Normalized Diluted EPS | 371.46% | 300.92% | 263.83% | 54.66% | 53.79% |
| Average Basic Shares Outstanding | 2.06% | 2.07% | 2.28% | 2.68% | 3.08% |
| Average Diluted Shares Outstanding | 7.60% | 4.79% | 5.01% | 2.68% | 3.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |